GNH USA

Europe — EMA

Merosap (Meropenem Anhydrous)

GNH USA supplies Merosap (Meropenem), a carbapenem antibiotic for complicated intra‑abdominal infections, urinary tract infections, hospital‑acquired

Meropenem Anhydrous

Request sourcing

1
Pack/s

What is Meropenem Anhydrous?

Meropenem, the active ingredient in Merosap, is a carbapenem antibiotic presented as an injectable powder for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia and sepsis in hospitalized patients.

GNH USA supplies Merosap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Meropenem Anhydrous used for?

Meropenem is a carbapenem antibiotic used to treat serious bacterial infections.

Complicated intra‑abdominal infections: provides broad‑spectrum coverage to eradicate mixed aerobic and anaerobic pathogens. Complicated urinary tract infections: eliminates resistant Gram‑negative organisms causing severe UTIs. Hospital‑acquired pneumonia: penetrates lung tissue to treat multidrug‑resistant respiratory pathogens. Severe sepsis and septic shock: offers rapid bactericidal activity essential for critically ill patients.

What are the side effects of Meropenem Anhydrous?

Adverse reactions may occur with meropenem therapy.

Common Side Effects: - Nausea or vomiting - Diarrhea, including mild Clostridioides difficile colonisation - Headache - Rash or mild skin erythema - Elevated liver enzymes - Infusion site erythema or phlebitis

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment or CNS disorders - Severe Clostridioides difficile‑associated colitis - Anaphylactic or anaphylactoid reactions - Acute renal toxicity - Neutropenia or agranulocytosis - Thrombocytopenia or other hematologic abnormalities

What precautions apply to Meropenem Anhydrous?

Key safety considerations should be observed before and during meropenem therapy.

Renal function: adjust dose in patients with impaired renal clearance. Allergy: avoid in individuals with known carbapenem hypersensitivity. Seizure risk: monitor patients with a history of CNS disorders or epilepsy. Pregnancy and lactation: use only if potential benefit justifies potential risk. Drug interactions: review concomitant medications for possible pharmacodynamic or pharmacokinetic effects. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

What does Meropenem Anhydrous interact with?

Meropenem may interact with several co‑administered drugs.

Major Interactions (Avoid): - Valproic acid: may reduce plasma levels of valproate, risking seizure breakthrough. - Probenecid: decreases renal clearance of meropenem, increasing toxicity risk. - High‑dose aminoglycosides: additive nephrotoxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: may exacerbate renal impairment. - NSAIDs: increase risk of renal dysfunction. - Warfarin: monitor INR as meropenem can alter anticoagulant effect.

Frequently asked questions

What is Merosap used for?+
Merosap contains meropenem, a carbapenem antibiotic indicated for the treatment of serious bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, and severe sepsis or septic shock in hospitalized patients.
How does meropenem work?+
Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan cross‑linking. This inhibition weakens the cell wall, causing osmotic rupture and rapid bacterial cell death.
What is the usual dose of Merosap?+
The dosing regimen for Merosap is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local antimicrobial guidelines. No fixed dose is provided here; the prescriber sets the appropriate regimen.
Is Merosap safe during pregnancy or breastfeeding?+
Safety data for meropenem in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.
How do I order Merosap from GNH USA?+
To order Merosap, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.
How does Merosap compare with other carbapenems?+
Merosap (meropenem) offers a broader spectrum against Gram‑negative and anaerobic organisms compared with imipenem‑cilastatin, and it has a lower propensity for inducing seizures. However, like all carbapenems, it requires dose adjustment in renal impairment and shares similar resistance concerns.
What are the storage and handling requirements for Merosap?+
Merosap should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the product. Once reconstituted, use according to the manufacturer’s stability guidelines and discard any unused solution after the recommended time.
How is Merosap administered?+
Merosap is supplied as a sterile powder for reconstitution. After adding the appropriate diluent, the solution is administered intravenously over a prescribed infusion period, typically 15‑30 minutes, under aseptic conditions.
What are the most serious risks associated with Merosap?+
Serious adverse events include seizures (especially in patients with renal dysfunction or CNS disorders), severe Clostridioides difficile‑associated colitis, anaphylaxis, and acute renal toxicity. Prompt recognition and management of these reactions are essential.
Who should not use Merosap?+
Merosap is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with severe renal impairment who have not received dose adjustment, and for those with a history of seizures.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Meropenem Anhydrous
Route
Intravenous Use
Manufacturer
Sapiens Pharmaceuticals Ltd
Origin
EU

Related products

Agenor

Agenor

Meropenem Anhydrous

Medochemie Ltd.
EU
Agenorem

Agenorem

Meropenem Anhydrous

Medochemie Ltd.
EU
Archifar

Archifar

Meropenem Anhydrous

Medochemie Ltd.
EU
Archifar

Archifar

Meropenem Anhydrous

Medochemie Ltd.
EU